Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Share-based Compensation (2017 - 2025)

Protagonist Therapeutics' Share-based Compensation history spans 9 years, with the latest figure at $10.7 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 17.68% year-over-year to $10.7 million; the TTM value through Dec 2025 reached $46.0 million, up 22.42%, while the annual FY2025 figure was $46.0 million, 22.42% up from the prior year.
  • Share-based Compensation for Q4 2025 was $10.7 million at Protagonist Therapeutics, up from $10.6 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $13.8 million in Q1 2025 and bottomed at $2.7 million in Q1 2021.
  • The 5-year median for Share-based Compensation is $7.2 million (2022), against an average of $7.7 million.
  • The largest annual shift saw Share-based Compensation soared 155.41% in 2021 before it increased 3.88% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $5.0 million in 2021, then grew by 9.71% to $5.5 million in 2022, then grew by 19.76% to $6.6 million in 2023, then soared by 37.75% to $9.1 million in 2024, then grew by 17.68% to $10.7 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Share-based Compensation are $10.7 million (Q4 2025), $10.6 million (Q3 2025), and $10.9 million (Q2 2025).